After a myocardial infarction (MI), an increase in the cardiac ratio of matrix metalloproteinases (MMPs) relative to their inhibitors (TIMPs) causes extracellular matrix modulation that leads to ventricular dilatation and congestive heart failure. Cell therapy can mitigate these effects. In this study, we tested whether increasing MMP inhibition via cell-based gene transfer of Timp-3 further preserved ventricular morphometry and cardiac function in a rat model of MI. We also measured the effect of treatment timing. We generated MI (coronary artery ligation) in adult rats. Three or 14 days later, we implanted medium (control) or vascular smooth muscle cells transfected with empty vector (VSMCs) or Timp-3 (C-TIMP-3) into the peri-infarct region (n = 15-24/group). We assessed MMP-2 and -9 expression and activity, TIMP-3, and TNF-α expression, cell apoptosis, infarct size and thickness, ventricular morphometry, and cardiac function (by echocardiography). Relative to medium, VSMCs delivered at either time point significantly reduced cardiac expression and activity of MMP-2 and -9, reduced expression of TNF-α, and increased expression of TIMP-3. Cell therapy also reduced apoptosis and scar area, increased infarct thickness, preserved ventricular structure, and reduced functional loss. All these effects were augmented by C-TIMP-3 treatment. Survival and cardiac function were significantly greater when VSMCs or C-TIMP-3 were delivered at 3 (vs. 14) days after MI. Upregulating post-MI cardiac TIMP-3 expression via cell-based gene therapy contributed additional regulation of MMP, TIMP, and TNF-α levels, thereby boosting the structural and functional effects of VSMCs transplanted at 3 or 14 days after an MI in rats. Early treatment may be superior to late, though both are effective.
INTRODUCTION
proteins can initiate the MMP/TIMP imbalance that leads to maladaptive remodeling after an MI. Specifically, a relative increase in MMP levels triggers remod-A main contributor to the adverse changes in ventricular dimensions and function that follow a myocardial eling of the extracellular matrix-a dynamic scaffold that supports cardiomyocytes and facilitates contraction infarction (MI) is a shift in the expression or activity of the degradative matrix metalloproteinase (MMP) enzymes (9) . These changes promote ventricular dilatation and dysfunction (24) and are not reversed by current medical relative to that of their natural tissue inhibitors (TIMPs). The TIMP family of protease inhibitors comprises four therapies (21). Reestablishing the balance by increasing TIMP expression has been shown to mitigate matrix proteins (TIMP-1, -2, -3, and -4) involved in the maintenance of tissue structure. The loss of any one of these remodeling and treat ischemic cardiomyopathy caused by an MI (5) , but establishing clinically relevant meth-washed with PBS and scraped to remove the endothelium. Pieces of tissue that adhered to the culture dish ods has been a challenge (30) . For example, chronic administration of MMP inhibitors was not useful were mixed with 5 ml Dulbecco's modified Eagle medium (DMEM) containing 20% fetal bovine serum to (12, 22, 25) , and gene therapies are nonspecific (25) .
We recently demonstrated that the beneficial para-obtain primary VSMCs. The primary cells were subsequently cultured in DMEM containing 10% fetal bovine crine effects of cell transplantation (8) are enhanced by genetically modifying the implanted cells for increased serum, 100 U/ml penicillin, and 100 µg/ml streptomycin for 30 min at 37°C and 5% CO 2 . The purity of the cul-cytokine production (11, 14, 32) . Potentially more clinically effective than traditional gene therapies, so-called tures was evaluated via immunohistochemical staining with monoclonal antibodies against α-smooth muscle cell-based gene therapies permit a temporally and spatially regulated release of the gene product. Using Timp-actin. VSMCs were transfected using liposomal lipofectamine 2000 (Invitrogen), either with a purified plasmid 3 knockout (Timp-3 −/− ) mice, we confirmed the unique role of TIMP-3 in maintaining ventricular dimensions comprising murine Timp-3 cDNA cloned into pcDNA3.1 + (Invitrogen) as previously described (13), or with an and preventing matrix disruption after an MI (28) and showed that reinstating TIMP activity via cell-based empty vector (control). Cellular Timp-3 mRNA levels were assessed using RT-PCR with specific primers as Timp-3 gene therapy enhanced the functional effects of cell therapy by transiently inhibiting MMP activity in previously described (4) . Timp-3 transfection was confirmed by the clear presence of a transfection band at the mutant mice (2). These findings have yet to be confirmed in wild-type animals.
the 464 bp location. In another study, we directly compared early versus late post-MI implantation of unmodified skeletal Surgical Procedures myoblasts into the infarcted myocardium in rats and With the rat under general anesthesia, a thoracotomy found that cardiac function was improved regardless of was performed and the left coronary artery was permathe timing of cell delivery (6) . In that study, myocardial nently ligated distal to the left atrial appendage. Ische-MMP activities were suppressed by cells delivered durmia was confirmed by the appearance of hypokinesis ing, but not after, the first week following an MI. We and pallor distal to the occlusion. The animals were ranhypothesized that, when treatment is given later after an domly separated into six groups (n = 28/group) and MI, an enhanced therapy (rather than cells alone) might allowed to recover. Three or 14 days later, a second thobe required to restore the MMP/TIMP ratio and prevent racotomy was performed, and VSMCs transfected 3 matrix disruption and ventricular dilatation.
days earlier with Timp-3 plasmid (C-TIMP-3 groups) or Here, we evaluate the effects of MMP inhibition by vector (VSMC groups) were delivered by three direct, cell-based gene transfer of Timp-3 on ventricular morintramyocardial injections (1 × 10 6 cells in 100 µl of phometry and cardiac function in a normal rat model of DMEM per injection) into three separate points in the MI and compare the results of early versus late treatment peri-infarct area. Control animals (medium groups) ( images were obtained in the parasternal short axis view Isolation, Transfection, and Characterization at the level of the papillary muscles. For each measureof Vascular Smooth Muscle Cells ment, three consecutive cardiac cycles were recorded and averaged by a single, blinded examiner. LV internal Vascular smooth muscle cells (VSMCs) were isolated from the adult female rat aorta as previously described diastolic dimension (LVIDd) and internal systolic dimension (LVIDs) were determined in M-mode (19). The aorta was minced into small pieces after it was imaging. LV end-diastolic volume (EDV) and end-sys-
The ratio of protein/actin was used to quantify MMP and TIMP-3 protein levels in each group. All antibodies tolic volume (ESV) were calculated using the following formulae: EDV = 1.047 × LVIDd 3 ; ESV = 1.047 × were from Chemicon. LVIDs 3 
. Percent ejection fraction (%EF) and fractional
Myocardial MMP Activity Measurement shortening (%FS) of the LV were calculated as follows:
Hearts (n = 5 per treated group, n = 3 per sham group) were snap frozen at 3 days after cell transplanta-LVIDs)/LVIDd] × 100 (3, 18) .
tion. The activities of myocardial MMP-2 and MMP-9 Morphometric Cardiac Assessment were quantified using gelatin zymography as described previously (28) . The values of gelatinase activity are After the rats were sacrificed at 28 days post-MI, hearts (n = 15-24 per group) were fixed with buffered expressed as intensity unit. 10% formalin at 20 mmHg ventricular pressure for 5
Myocardial Tumor Necrosis Factor-α (TNF-α) days. The fixed hearts were cut into 1-mm-thick trans-Expression Measurement verse slices from apex to base and photographed. Images were analyzed by a blinded observer using ImageJ soft-Myocardial tissue (n = 9 hearts per treated group, n = 4 per sham group) was homogenized and the super-ware. The border between infarcted and noninfarcted myocardium was clearly identifiable in each image natant was collected. Tumor necrosis factor-α (TNF-α) levels were quantified using an enzyme-linked immu-(infarcted myocardium appeared visibly thinner and paler in color than noninfarcted myocardium). Scar area nosorbent assay (commercial TNF-α ELISA kit, Invitrogen Canada Inc., Burlington, Canada, Catalog and thickness were calculated using computed planimetry as we have previously described (27). Briefly, both # KRC3011, used according to manufacturer's instructions). TNF-α concentrations were calculated based on apical and basal sections were digitally photographed and quantified. We calculated the epicardial surface a standard curve. Each sample was analyzed in triplicate and then averaged. areas of the LV free wall (LVFW) and any scar tissue in the LVFW as the sum of the epicardial length times Myocardial Inflammation Measurement the section thickness (1 mm). We next calculated the scar surface area as a percentage of the LVFW area as
The number of infiltrating inflammatory cells was measured by a semiquantitative method (assessment of follows: (epicardial scar area)/(epicardial LVFW area) × 100. Scar thickness was presented as an average of wall cell nuclear density) from H&E-stained slides 3 days following cell implantation (n = 5 per treated group, n = thickness measurements taken at the middle and at each edge of the scar area.
3 per sham group). The degree of infiltration was classified on the scale of + (indicating the lowest infiltration) Ultrastructural Cardiac Analysis to +++ (indicating the highest infiltration).
For transmission electron microscopy (TEM), we
Myocardial Apoptosis Measurement sampled cardiac tissue from the peri-infarct region. Small blocks (0.5-1 mm 3 ) of cardiac tissue from the For this analysis, terminal dUTP nick-end labeling (TUNEL) assay was performed on tissue sections 3 days peri-infarct (border) region were fixed in 1% glutaraldehyde in phosphate buffer and then sent to the Depart-following implantation (n = 5 per treated group, n = 3 per sham group) with an in situ Cell Death Detection kit ment of Cardiovascular Pathology at the Harbin Medical University (Harbin, China) for electron microscopic (Roche Inc.) as previously described (28) . Apoptotic cell death was determined by counting the number of analysis. The samples were postfixed with 1% osmium tetroxide, embedded, sliced, and photographed as we TUNEL-positive nuclei per microscopic field (200× equals 0.4 mm 2 ) in five fields per slide and then averaged. have previously reported (17) .
Myocardial MMP and TIMP-3 Statistical Methods Expression Measurement
Results are expressed as mean ± standard deviation of the mean. Analyses were performed using GraphPad Hearts [n = 9 per treated group, n = 4 per sham group (normal controls)] were snap frozen. The heart homoge-Prism software (v.4) with the critical α-level set at p < 0.05. Mortality rates were compared using a chi-square nate was treated with an appropriate extraction buffer and then protein expression levels of MMP-2, MMP-9, test. Survival was analyzed with Kaplan-Meier survival curves and log-rank statistics. Two-way analyses of and TIMP-3 were measured by Western blot (9) . Each sample contained tissue from the infarct area and the variance (with Bonferroni multiple comparison posttests to specify differences between the groups) compared the remote area. We used housekeeping protein (β-actin) as the internal standard for the MMP and TIMP-3 calculation.
effects of treatment (sham, medium, VSMC, C-TIMP-3) and treatment timing (3 vs. 14 days after MI) on cardiac TIMP-3 reduced the magnitude of ventricular dilatation, scar area, and wall thinning recorded in control animals. morphometry, cardiac function, levels of MMP, TIMP-3, and TNF-α, and cell apoptosis.
Overall LV geometry was further preserved by the geneenhanced cells, and there was some evidence that cell RESULTS (and cell-based gene) treatment may be most effective if Mortality delivered early, rather than later, after an MI. Mortality rates were calculated for the 28-day dura-Left Ventricular Function tion of the experiment. Whether implantation was at 3
By echocardiography, %EF and %FS were signifior 14 days after MI, mortality rates were significantly cantly increased at 28 days after MI in the VSMC higher (p < 0.05) in the medium groups than in the groups (p < 0.05 vs. medium), with further improve-VSMC groups and were the lowest in the C-TIMP-3 ments in the C-TIMP-3 groups (p < 0.05 vs. VSMC). groups (p < 0.05 vs. VSMC) ( Fig. 1a ). Comparing early Also, %EF and %FS were greatest in VSMC and Cand later treatment, both VSMC and C-TIMP-3 groups TIMP-3 groups that received cells at 3 days (vs. 14 experienced significantly less mortality when the cells days) after MI (p < 0.05 for all comparisons), indicating were delivered at 3 days rather than 14 days after MI that there was a benefit associated with early cell trans-(p < 0.05 for both groups). Log-rank statistics confirmed plantation ( Fig. 4 ). that percent survival was significantly higher (p < 0.05) in animals that received cells at the 3-day time point MMP and TIMP-3 Protein Expression (Figs. 1b, c). Treatment timing did not affect mortality Myocardial protein levels of MMP-2, MMP-9, and in the control groups.
TIMP-3 were evaluated at 28 days after MI. The analy-Left Ventricular Morphometry and Ultrastructure sis revealed stronger MMP and weaker TIMP-3 protein bands in the medium control group compared with the Measures of LV dilatation (LVIDd and LVIDs) and LV volumes (EDV and ESV) assessed using echocardi-VSMC and C-TIMP-3 groups (Fig. 5a ). Inversely, compared with levels recorded in control animals (medium ography at 28 days post-MI ( Fig. 2) , as well as LV volume indexed by animal body weight (Table 1) , indicated groups), there were significant decreases in MMP-2 and MMP-9 protein levels in those that received VSMCs that LV structure was significantly preserved (vs. medium) after cell treatment (VSMC), with a further (p < 0.01 vs. medium) ( Fig. 5b , c) with further reductions in animals that received the gene-enhanced cells beneficial effect after treatment with gene-enhanced cells (C-TIMP-3) (p < 0.05 for all comparisons). Simi-(p < 0.05 vs. VSMC) (Fig. 5b, c) . Meanwhile, TIMP-3 protein levels were significantly increased in the VSMC larly, myocardial scars were the smallest and thickest in the C-TIMP-3 groups (p < 0.05 vs. VSMC) and the groups (p < 0.01 vs. medium), and most increased in the C-TIMP-3 groups (p < 0.05 vs. VSMC) ( Fig. 5d ). largest and thinnest in the medium groups (p < 0.01 vs. VSMC, C-TIMP-3) ( Fig. 3a-c) .
MMP Activity An ultrastuructural analysis of myocardial tissue at the border zone collected at 28 days after MI revealed MMP activities were measured by gel zymography at 3 days after cell transplantation (Fig. 6a ). The MMP-2 clear group differences in histology (Fig. 3d ). In the medium group, cardiomyocytes in the border area had and -9 activities were highest in the day 3 and day 14 medium groups (Fig. 6a-c) , followed by the day 3 and condensed nuclei, fractured and dissolved mitochondrial cristae, and low matrix density. In the VSMC group, the day 14 VSMC groups (p < 0.05 vs. medium group) ( Fig.  6a-c) , and were lowest in the day 3 C-TIMP-3 groups sarcomeres were clear with visible myocyte contraction bands, and the mitochondria were only mildly swollen.
(p < 0.05 vs. VSMC group) ( Fig. 6a-c) . There was no difference between day 14 VSMC and C-TIMP-3 groups. In the C-TIMP-3 group, the cardiomyocytes were in good condition, with rich cytoplasmic organelles TNF-α Expression, Inflammation, and Apoptosis (including visible nucleoli), intact mitochondrial cristae, and balanced matrix density.
By a semiquantitative method (assessment of cell nuclear density), the number of infiltrating cells (Fig. Most of these effects were not dependent on timing of treatment, with two exceptions: although treatment 7a, arrows) was highest in the medium group (+++), followed by the VSMC group (++), and was lowest in the timing did not affect ventricular dimensions in the medium groups, LVIDd and LV volume indices were C-TIMP-3 group (+) at 3 days after cell transplantation (Fig. 7a ). significantly smaller following the delivery of VSMC or C-TIMP-3 at 3 days, rather than 14 days, after MI (p < At 28 days after the MI, TNF-α levels were elevated in control animals (in medium vs. sham groups). In com-0.05 for all comparisons) ( Fig. 2a, Table 1 ). Therefore, treatment with VSMCs or VSMCs overexpressing parison to levels in the medium group, expression of this cytokine was significantly reduced in animals that received VSMCs (p < 0.01 vs. medium) ( Fig. 7a ) and ment with the gene-enhanced cells (p < 0.01 vs. VSMC) ( Fig. 7b ). TNF-α levels did not vary with the timing Time of Transplantation of treatment.
(After MI)
At 3 days after cell transplantation, the number of apoptotic cells (Fig. 8a, arrows) vs. medium) (Fig. 8b) , and was lowest in the C-TIMP- effect on functional outcome was slightly, but significantly, weaker and mortality was increased when the cells (modified or not) were delivered later after the to heart failure. For example, animals with chronic myocardial MMP-1 overexpression experience marked car-injury (at 14 days compared to 3 days post-MI), we found that cell-based Timp-3 gene therapy was superior diac dysfunction (15) , and mice lacking a natural MMP inhibitor (Timp-3 −/− mice) have increased end-diastolic to cell therapy alone even at the 14-day time point.
MMPs contribute to tissue development, morphogen-volumes and pressures and decreased contractility after an MI (28) . LV dilatation and rupture are decreased after esis, and inflammation (23,29) and are involved in the pathological progression of tissue and organ abnormali-myocardial injury in mice that lack MMP-9 (Mmp-9 −/− mice) (5) . We previously reported that increased MMP ties. Thus, after an MI, MMPs have a role in the progressive ventricular dilatation and dysfunction that leads activity and decreased TIMP-3 expression are associated with human heart failure (9) . Here, we found evidence the VSMC and C-TIMP-3 groups. Despite the fact that in situ zymography was not used for the analysis of of enhanced myocardial MMP-2 and -9 protein expression by Western blot after an MI in rats (medium vs.
MMP activity, which is a limitation of our study, we demonstrated that implantation of smooth muscle cells sham groups) and increased MMP-2 and -9 activity by gel zymography in the medium group compared with or cells with the Timp-3 gene significantly decreased MMP-2 and -9 activity and improved the recovery of in a mutant mouse model, that modifying the donor cells to overexpress TIMP-3 before implantation contributes myocardial function following MI. Indeed, we found that enhanced myocardial MMP activity in untreated transient MMP inhibition that enhances the cells' paracrine effects and boosts the functional benefits of post-animals was associated with LV dilatation and functional loss. But cell therapy or cell-based Timp-3 gene MI cell therapy (2) . Our current results confirm this pattern in a normal rat model of MI, suggesting that cell-therapy administered within 14 days of the MI rebalanced the MMP/TIMP ratio and mitigated the harmful based gene therapy could improve treatment outcomes for aging patients whose responses to implanted cells cardiac effects, providing support for the theory that post-MI ventricular remodeling and cardiac dysfunction are diminished. Another factor affecting clinical outcomes for cell are triggered by a myocardial MMP/TIMP imbalance.
In addition, TNF-α, an inflammatory cytokine associ-therapy is time of implantation. Cell therapy is normally less effective when it is delivered during the late stages ated with cardiac remodeling and cell apoptosis, is upregulated in the infarcted myocardium (10) and is of congestive heart failure rather than soon after a myocardial injury (16). Here, we found that functional resto-known to increase MMP gene expression (26) . We quantified the apoptotic cells in the border zone of the ration was less pronounced when the cell or cell-based gene treatment was delayed (to 14 vs. 3 days after the infarct heart by TUNEL staining and found that, based on cell shape, most apoptotic cells were cardiomyocytes. MI), perhaps because the cells are more effective if delivered during the earlier stages of ventricular dilata-These data are in agreement with our previously published data (28) . We also quantified TUNEL-stained tion, which increases with time after MI. Also, the first week after an MI is a period of intense inflammatory inflammatory cells and found no significant difference in the number of apoptotic inflammatory cells among activity. Since significantly increased MMP-2 and -9 activity at 3 days after cell transplantation has been the medium, VSMC, and C-TIMP-3 groups (data not shown). These data suggest that one of the mechanisms observed in the myocardium, these proteases could be contributed by myocardial cells as well as by infiltrating of the beneficial effect of cell transplantation or cellbased TIMP-3 overexpression was likely the limitation cells following injury. In our current study, we found that the number of infiltrating cells was highest in the of cardiomyocyte loss. Thus, the enhanced benefits of TIMP-3 overexpression compared to unmodified VSMCs medium group, followed by the VSMC group, then the C-TIMP-3 group. These data corroborate with the myo-may have involved a TIMP-3-mediated inhibition of TNF-α converting enzyme (TACE) (1,31) and a resul-cardial TNF-α production in the different groups. Therefore, a large part of the MMP activity in the medium, tant drop in cardiac TNF-α production, thereby limiting cardiomyocyte loss.
VSMC, and C-TIMP-3 groups could most likely arise from infiltrating inflammatory cells. Thus, gene-trans-Two experimental models commonly used to study the pathophysiological processes associated with MI are fected cells may have not only directly inhibited MMP-2 and -9 activity, but also suppressed early myocardial ischemia/reperfusion and permanent coronary artery ligation. While ischemia/reperfusion is the preferred inflammation. We expected that overexpressing TIMP-3 in the implanted cells would boost their effects. Indeed, model for assessing therapies and outcomes following reperfusion in an acute MI setting, the permanent liga-the gene-enhanced cells showed greater preservation of ventricular volumes, wall thickness, and cardiac func-tion model used here is useful for studying cardiac remodeling and outcomes later after an MI (in this case, tion than did unmodified VSMCs at both time points. Also, functional outcomes after late implantation of at 28 days). The pattern of ventricular dilatation and dysfunction manifested in our model (28) is comparable gene-enhanced cells were better than those after early implantation of unmodified cells, and morphometric out-to that seen in patients who progress rapidly to heart failure after an MI, perhaps due to an inadequate TIMP comes were similar in response to cell-based gene therapy delivered at either time point. injury response. Cell therapy alone has repeatedly been demonstrated to significantly improve ventricular func-We conclude that short-term amplification of TIMP-3 expression via cell-based gene therapy improves healing tion after MI in animals (7, 11, 19, 20, 33) , primarily due to paracrine effects that stimulate angiogenesis, reduce after an MI in rats; this approach may provide a clinically relevant option for patients with ischemic cardio-apoptosis, increase bone marrow cell recruitment, and decrease matrix modulation (8) . Unfortunately, data myopathy. However, this study did not evaluate angiogenesis, marrow-derived progenitor cell recruit-from clinical trials indicate that the approach is less effective in patients who have experienced an MI, per-ment, or myofibroblast activity in the heart-all of which are believed to be affected by cell or cell-based haps because the paracrine effects of implanted cells are diminished in aged patients. We have previously shown, gene therapy. A more detailed understanding of the 
